CN1901894A - 抑制剂成像剂 - Google Patents

抑制剂成像剂 Download PDF

Info

Publication number
CN1901894A
CN1901894A CNA2004800403628A CN200480040362A CN1901894A CN 1901894 A CN1901894 A CN 1901894A CN A2004800403628 A CNA2004800403628 A CN A2004800403628A CN 200480040362 A CN200480040362 A CN 200480040362A CN 1901894 A CN1901894 A CN 1901894A
Authority
CN
China
Prior art keywords
imaging
radioactive
imaging agent
formula
agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA2004800403628A
Other languages
English (en)
Chinese (zh)
Inventor
A·库伯特森
M·索巴肯
E·布格特
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GE Healthcare Ltd
Original Assignee
GE Healthcare Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by GE Healthcare Ltd filed Critical GE Healthcare Ltd
Publication of CN1901894A publication Critical patent/CN1901894A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6425—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a receptor, e.g. CD4, a cell surface antigen, i.e. not a peptide ligand targeting the antigen, or a cell surface determinant, i.e. a part of the surface of a cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0002—General or multifunctional contrast agents, e.g. chelated agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/04—X-ray contrast preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Radiology & Medical Imaging (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
  • Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
CNA2004800403628A 2003-11-14 2004-11-12 抑制剂成像剂 Pending CN1901894A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0326546.9 2003-11-14
GBGB0326546.9A GB0326546D0 (en) 2003-11-14 2003-11-14 Inhibitor imaging agents

Publications (1)

Publication Number Publication Date
CN1901894A true CN1901894A (zh) 2007-01-24

Family

ID=29726529

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA2004800403628A Pending CN1901894A (zh) 2003-11-14 2004-11-12 抑制剂成像剂

Country Status (16)

Country Link
US (1) US20070104644A1 (https=)
EP (1) EP1682113B1 (https=)
JP (1) JP5043438B2 (https=)
KR (1) KR20060118479A (https=)
CN (1) CN1901894A (https=)
AT (1) ATE384519T1 (https=)
AU (1) AU2004290950A1 (https=)
BR (1) BRPI0416528A (https=)
CA (1) CA2545267A1 (https=)
DE (1) DE602004011553T2 (https=)
ES (1) ES2299884T3 (https=)
GB (1) GB0326546D0 (https=)
MX (1) MXPA06005355A (https=)
NO (1) NO20062118L (https=)
RU (1) RU2006117298A (https=)
WO (1) WO2005049005A1 (https=)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102105174B (zh) * 2008-07-22 2014-07-02 伯拉考成像股份公司 对金属蛋白酶选择性的诊断剂
CN103980277A (zh) * 2014-05-27 2014-08-13 青岛大学 一种叶酸巯基化衍生物的制备方法

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200630337A (en) * 2004-10-14 2006-09-01 Euro Celtique Sa Piperidinyl compounds and the use thereof
WO2007030012A2 (en) * 2005-09-05 2007-03-15 Stichting Voor De Technische Wetenscahappen Extracellular matrix imaging
FR2891830B1 (fr) 2005-10-07 2011-06-24 Guerbet Sa Composes a chaines aminoalcools courtes et complexes metalliques pour l'imagerie medicale
GB0520527D0 (en) * 2005-10-10 2005-11-16 Ge Healthcare Ltd Automated method
WO2007094683A1 (en) 2006-02-15 2007-08-23 Ge Healthcare As Contrast agents
BRPI0709677A2 (pt) * 2006-03-29 2011-07-19 Novartis Ag inibidores seletivos das mmp à base de hidroxamato
WO2007110449A1 (en) * 2006-03-29 2007-10-04 Euro-Celtique S.A. Benzenesulfonamide compounds and their use
TW200815353A (en) * 2006-04-13 2008-04-01 Euro Celtique Sa Benzenesulfonamide compounds and their use
US8937181B2 (en) * 2006-04-13 2015-01-20 Purdue Pharma L.P. Benzenesulfonamide compounds and the use thereof
GB0610395D0 (en) * 2006-05-25 2006-07-05 Ge Healthcare Ltd Novel imaging agents
JP2010513476A (ja) * 2006-12-20 2010-04-30 ジーイー・ヘルスケア・アクスイェ・セルスカプ 造影剤
US8399486B2 (en) * 2007-04-09 2013-03-19 Purdue Pharma L.P. Benzenesulfonyl compounds and the use thereof
US8765736B2 (en) * 2007-09-28 2014-07-01 Purdue Pharma L.P. Benzenesulfonamide compounds and the use thereof
EP2119690A1 (en) * 2008-05-14 2009-11-18 Academisch Medisch Centrum bij de Universiteit van Amsterdam Radiolabelled MMP selective compounds
JP5322527B2 (ja) * 2008-07-17 2013-10-23 浜松ホトニクス株式会社 アポトーシスの検出に適した化合物
WO2010138720A2 (en) * 2009-05-27 2010-12-02 The Scripps Research Institute Compounds and methods for chelating metals in aqueous solutions
ES2576853T3 (es) * 2009-07-03 2016-07-11 Inserm - Institut National De La Santé Et De La Recherche Médicale Compuestos dirigidos al receptor del manosa 6-fosfato independiente de cationes
US9023318B2 (en) * 2011-06-08 2015-05-05 Siemens Medical Solutions Usa, Inc. Compounds with matrix-metalloproteinase inhibitory activity and imaging agents thereof
US8871189B2 (en) * 2011-11-30 2014-10-28 Mallinckrodt Llc MMP-targeted therapeutic and/or diagnostic nanocarriers
GB202012671D0 (en) * 2020-08-13 2020-09-30 Nrf Ithemba Labs Theranostic Compounds
WO2025045168A1 (zh) 2023-09-01 2025-03-06 江苏恒瑞医药股份有限公司 一种大环化合物及其用途

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5714465A (en) * 1989-05-19 1998-02-03 Amgen Inc. Method of inhibiting tumor cell dissemination with a metalloproteinase inhibitor
US5863949A (en) * 1995-03-08 1999-01-26 Pfizer Inc Arylsulfonylamino hydroxamic acid derivatives
PT895988E (pt) * 1997-08-08 2002-09-30 Pfizer Prod Inc Derivados do acido arilsulfonilamino-hidroxamico
AU730248B2 (en) * 1997-08-08 2001-03-01 Pfizer Products Inc. Aryloxyarylsulfonylamino hydroxamic acid derivatives
IL127496A0 (en) * 1997-12-19 1999-10-28 Pfizer Prod Inc The use of MMP inhibitors for the treatment of ocular angiogenesis
PT952148E (pt) * 1998-04-10 2004-09-30 Pfizer Prod Inc Derivados de acido ciclobutil-ariloxiarilsulfonilamino-hidroxamico
DK1210326T3 (da) * 1999-08-18 2004-06-21 Warner Lambert Co Hydroxamsyreforbindelser, der er nyttige som matrixmetalloproteinaseinhibitorer
IL138686A0 (en) * 1999-10-01 2001-10-31 Pfizer Prod Inc α- SULFONYLAMINO HYDROXAMIC ACID INHIBITORS OF MATRIX METALLOPROTEINASES FOR THE TREATMENT OF PERIPHERAL OR CENTRAL NERVOUS SYSTEM DISORDERS
US6656448B1 (en) * 2000-02-15 2003-12-02 Bristol-Myers Squibb Pharma Company Matrix metalloproteinase inhibitors
DE60114022T2 (de) * 2000-05-30 2006-07-13 Board Of Governors Of Wayne State University, Detroit Matrix metalloproteinase-inhibitoren
WO2004069365A1 (en) * 2003-02-10 2004-08-19 Ge Healthcare Limited Diagnostic imaging agents with mmp inhibitory activity

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102105174B (zh) * 2008-07-22 2014-07-02 伯拉考成像股份公司 对金属蛋白酶选择性的诊断剂
CN103980277A (zh) * 2014-05-27 2014-08-13 青岛大学 一种叶酸巯基化衍生物的制备方法

Also Published As

Publication number Publication date
EP1682113A1 (en) 2006-07-26
ATE384519T1 (de) 2008-02-15
DE602004011553D1 (de) 2008-03-13
JP5043438B2 (ja) 2012-10-10
MXPA06005355A (es) 2006-07-10
BRPI0416528A (pt) 2007-01-09
KR20060118479A (ko) 2006-11-23
ES2299884T3 (es) 2008-06-01
GB0326546D0 (en) 2003-12-17
DE602004011553T2 (de) 2009-03-26
JP2007511494A (ja) 2007-05-10
WO2005049005A1 (en) 2005-06-02
US20070104644A1 (en) 2007-05-10
RU2006117298A (ru) 2007-12-20
NO20062118L (no) 2006-05-11
AU2004290950A1 (en) 2005-06-02
CA2545267A1 (en) 2005-06-02
EP1682113B1 (en) 2008-01-23

Similar Documents

Publication Publication Date Title
CN1901894A (zh) 抑制剂成像剂
CN1292798C (zh) 乙二半胱氨酸(ec)－药物缀合物
CN1230441C (zh) 结合整联蛋白的肽衍生物
CN1622832A (zh) 用于动脉粥样硬化和易病变性斑块成像的标记的巨噬细胞清除剂受体拮抗剂
CN1822861A (zh) 稳定的放射性药物组合物及制备方法
CN1925878A (zh) 供心肌灌注成像所用的对比剂
CN1905904A (zh) 包含半胱氨酸天冬氨酸蛋白酶3抑制剂的新型显像剂
US20080279765A1 (en) Novel Imaging Agents for Fibrosis
US20120244074A1 (en) Labelled integrin binders
CN1723042A (zh) 乙二半胱氨酸(ec)－药物结合物、组合物及用于组织特异性疾病显像的方法
CN101076357A (zh) 金属蛋白酶抑制剂显像剂
CN1968963A (zh) 基于肽的化合物
US20080292547A1 (en) Novel Imaging Agents for Fibrosis
CN1720050A (zh) 包含巴比妥酸衍生物的改进成象剂
CN101039702A (zh) 作为靶向试剂用于内皮－特异性体内转导的热激蛋白
US20080286201A1 (en) Caspase-3 Substrate Comprising Imaging Agents
WO2008003954A1 (en) Dye imaging agents
CN1901941A (zh) 血管紧张素ii与成像部分的缀合物
US20080279771A1 (en) Novel Imaging Agents for Cancer
HK1107102A (en) Peptide-based compounds

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C12 Rejection of a patent application after its publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20070124